Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic Non-Small Cell Lung Cancer and Tumor PD-L1 <1%: a Pooled Analysis

INTRODUCTION: Nivolumab plus ipilimumab-based treatment regimens have shown long-term, durable efficacy benefit in patients with metastatic non-small cell lung cancer (NSCLC). Here we report clinical outcomes from a pooled analysis of patients with metastatic NSCLC and tumor programmed death ligand 1 (PD-L1) <1% treated with first-line nivolumab plus ipilimumab with or without two cycles of chemotherapy versus up to four cycles of chemotherapy in the randomized phase 3 CheckMate 227 and CheckMate 9LA studies. METHODS: Patients were aged

• Peters, S.
• Paz-Ares, L. G.
• Reck, M.
• Carbone, D. P.
• Brahmer, J. R.
• Borghaei, H.
• Lu, S.
• O'Byrne, K. J.
• John, T.
• Ciuleanu, T. E.
• Schenker, M.
• Caro, R. B.
• Nishio, M.
• Cobo, M.
• Lee, J. S.
• Zurawski, B.
• Pluzanski, A.
• Aoyama, T.
• Tschaika, M.
• Devas, V.
• Grootendorst, D. J.
• Ramalingam, S. S.